This morning, Citigroup downgraded shares of Alexion Pharmaceuticals (NASDAQ:ALXN) from buy to hold citing valuation. The stock has gained more than 18% over the past two months and is pushing up against the firm's price target of $91 per share.
In morning trading, shares of Alexion were retreating, pulling back about 1.1% so far.
And Goldman Sachs lowered its price target on shares of Expeida (NASDAQ:EXPE) to $26 as margins are expected to shrink this year. With the lower price target, Goldman reduced its EPS estimates through 2012 and maintained its neutral rating.
Shares of Expedia were sharply lower on Friday, falling more than 15% this morning.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.